MMP13 and osteoarthritis: Recently, a Smo‐specific inhibitor named taladegib was verified to be a promising agent for osteoarthritis treatment, since it controlled chondrocyte hypertrophy by down‐regulating the expression of MMP13, collagen type X and RUNX2 via Smo/Gli1 signalling.28